Silphium Asset Management LTD Cure Vac N.V. Transaction History

Silphium Asset Management LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Jan 30, 2025	SELL	$2.74 - $3.79 $274,000 - $379,000	-100,000 Closed	0 $0
Q1 2024 Jan 30, 2025	SELL	$2.94 - $4.34 $220,500 - $325,500	-75,000 Reduced 42.86%	100,000 $303 Million
Q4 2023 Jan 30, 2025	BUY	$3.96 - $6.41 $99,000 - $160,250	25,000 Added 16.67%	175,000 $737 Million
Q3 2023 Jan 30, 2025	BUY	$6.5 - $10.77 $162,500 - $269,250	25,000 Added 20.0%	150,000 $1.02 Billion
Q2 2023 Jan 30, 2025	BUY	$6.69 - $12.25 $836,250 - $1.53 Million	125,000 New	125,000 $1.3 Billion

12.2M

164K

117K

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $725M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

Get notified when there are updates to the investment portfolio of Silphium Asset Management LTD, based on Form 13F filings with the SEC.

Stay updated on Silphium Asset Management LTD with notifications on news.